|
|
{{if listFind(vars.channel_names, "MSIF News")}} {{endif}}  {{if listFind(vars.channel_names, "MSIF News")}} {{endif}} {{if listFind(vars.channel_names, "MSIF News")}} 
MSIF News
{{endif}}
|
{{if listFind(vars.channel_names, "People With MS News")}} {{endif}}  {{if listFind(vars.channel_names, "People With MS News")}} {{endif}} {{if listFind(vars.channel_names, "People With MS News")}} 
Profile of the Month
{{endif}}
|
{{if listFind(vars.channel_names, "Research News")}} {{endif}}  {{if listFind(vars.channel_names, "Research News")}} {{endif}} {{if listFind(vars.channel_names, "Research News")}} 
Research News
{{endif}}
|
{{if listFind(vars.channel_names, "MS Society News")}} {{endif}}  {{if listFind(vars.channel_names, "MS Society News")}} {{endif}} {{if listFind(vars.channel_names, "MS Society News")}} 
MS News
{{endif}}
|
|
|
|
Making Connections
US Food and Drug Administration approved return to market of Tysabri® (natalizumab)
The US Food and Drug Administration (FDA) has approved Tysabri’s return to the US market for relapsing MS. Biogen Idec and Elan Pharmaceuticals, who produced the drug, hope to make it available in July. Positive results from two clinical trials showing that Tysabri significantly reduced the risk of sustained progression of disability and the rate of clinical relapse in those with relapsing MS.
The approval hinges on a mandatory registration program for patients and prescribing physicians to minimize the risks that patients will develop PML (progressive multifocal leukoencephalopathy), caused by a common virus called the JC virus. Three people who had been in clinical trials involving Tysabri developed PML, two of whom died.
For more details, please click here.
|
{{if listFind(vars.channel_names, "MSIF News")}}
|
|
MSIF News
 |
 |
| Summaries of new MSIF activities, events, projects, programmes, resources, publications and more. |
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "People With MS News")}}
|
|
Profile of the Month
|
|
| Summaries of news, views and achievements from people with MS around the world. |
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "Research News")}}
|
|
Research News
|
|
| Summaries of all the latest research findings on MS selected by a team based at the Institute of Neurology, London. |
The contribution of demyelination to axonal loss in multiple sclerosis
This study found poor correlations between MS plaque load and axonal density measured histologically in the motor and sensory pathways of the brain and spinal cord. The authors hypothesise that axonal degeneration may, at least sometimes, be separate from demyelination.
authors: DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM.
source: Brain. 2006 Jun;129(Pt 6):1507-16. Epub 2006 Apr 5.
read more
Nogo in multiple sclerosis: Growing roles of a growth inhibitor.
Nogo protein is a component of myelin which inhibits regeneration of damaged axons. This article reviews what is known of the immunology of Nogo in relation to potential treatments aimed at inhibiting its function and hence promoting axonal repair.
authors: Fontoura P, Steinman L.
source: J Neurol Sci. 2006 Jun 15;245(1-2):201-10. Epub 2006 May 6.
read more
Interferons and cognition
It is known that interferons reduce the number of MS relapses but it is not known whether this has any beneficial effects on cognitive function. This paper reviews trials in different types of MS and concludes that more work is needed, with recommendations for future trial design.
authors: Montalban X, Rio J.
source: J Neurol Sci. 2006 Jun 15;245(1-2):137-40. Epub 2006 Apr 19.
read more
Functional magnetic resonance imaging and cognition at the very early stage of MS.
This paper reviews the results of recent functional MRI studies which suggest that cognitive dysfunction in the early stages of MS may be due to interruption of white matter networks. They found cortical activations suggesting that people with MS may partially compensate for this by exerting greater cognitive control, which could have implications for therapy.
authors: Audoin B, Van Au Duong M, Malikova I, Confort-Gouny S, Ibarrola D, Cozzone PJ, Pelletier J, Ranjeva JP.
source: J Neurol Sci. 2006 Jun 15;245(1-2):87-91. Epub 2006 Apr 21.
read more
Effects of donepezil on memory and cognition in multiple sclerosis
This small single-centre randomised double blind placebo-controlled trial showed that donepezil, an anticholinesterase inhibitor used in Alzheimers, showed some benefits in cognitive measures. This promising result needs confirmation with larger, multi-centre studies.
authors: Christodoulou C, Melville P, Scherl WF, Macallister WS, Elkins LE, Krupp LB.
source: J Neurol Sci. 2006 Jun 15;245(1-2):127-36. Epub 2006 Apr 19.
read more
Are there protective treatments for cognitive decline in MS?
This paper reviews the evidence behind pharmacological and non-pharmacological treatments for cognitive dysfunction in MS, concluding that anticholinesterase inhibitors show promise and more work is needed.
authors: Amato MP, Portaccio E, Zipoli V.
source: J Neurol Sci. 2006 Jun 15;245(1-2):183-6. Epub 2006 Apr 27.
read more
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "MS Society News")}}
|
|
MS News
|
|
| Summaries of MS news from websites around the world. If you have MS news to share with the international MS community, please click here. |
MS Life Convention
source: UK MS Society
Summaries of presentations from the UK MS Society's convention, MS Life, which took place in April 2006, are now available to download.
read more
|
{{endif}}
|
|
Tell a friend
The email you subscribed with us is {{print email}}
Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.
If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.
If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here
Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org
|
|
